CAMBRIDGE, MA--(Marketwire - July 23, 2012) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Tuesday, July 24, 2012 to discuss 36-week 6-minute walk test results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).
The conference call may be accessed by dialing 866.783.2139 for domestic callers and 857.350.1598 for international callers. The passcode for the call is 77518015. Please specify to the operator that you would like to join the "Sarepta Therapeutics 36-Week Clinical Results Call." The conference call will be webcast live under the events section of Sarepta's website at www.sareptatherapeutics.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.